Beigene’s Lymphoma Treatment Zanubrutinib Shows High Response Rates in Chinese Phase 1 Trial
News
BeiGene‘s investigational zanubrutinib is showing promising response rates, ranging from 42% to 100%, in several B-cell lymphoma subtypes, preliminary data from a Chinese Phase 1 trial show. Treatment was also well-tolerated. Jun ... Read more